Tokorozawa, Japan

Tomohiro Neichi


Average Co-Inventor Count = 10.3

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1982-1984

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tomohiro Neichi: Innovator in Pharmaceutical Chemistry

Introduction

Tomohiro Neichi is a prominent inventor based in Tokorozawa, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on various compounds that have therapeutic applications.

Latest Patents

Neichi holds 2 patents that showcase his expertise in developing novel pharmaceutical compositions. His latest patents include a dibenzoxazepine derivative, which is a compound that exhibits lipid-lowering activity, blood sugar-lowering activity, and the ability to inhibit platelet aggregation. This compound is particularly useful in treating diseases related to circulatory organs. Additionally, he has developed a nicotinamide derivative, specifically a novel compound known as 1,2-bis(nicotinamido)propane, which is effective in preventing cerebral vasospasms and lowering lipoperoxide levels in the blood.

Career Highlights

Neichi is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at this company has allowed him to focus on innovative drug development, contributing to advancements in medical treatments.

Collaborations

Throughout his career, Neichi has collaborated with notable colleagues, including Yasushi Murakami and Hiroshi Nakakimura. These collaborations have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Tomohiro Neichi's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the medical field positively, showcasing the importance of innovation in developing effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…